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A B S T R A C T
The standard armamentarium of tests that are used by pulmonologist are laboratory tests, pulmonary function tests,
different radiological techniques (conventional chest-X rays, HRCT scans, etc) and pathohistological analyses of biop-
sies. The minimally invasive bronchoalveolar lavage (BAL) procedure, in addition to methods earlier mentioned, is an
important diagnostic instrument that can facilitate the diagnosis of various diffuse lung diseases (DLD). BAL fluid
white blood cell profiles are analyzed, malignant cells looked for, and in certain circumstances particular stains are per-
formed to detect yet other cell types. Additionally, BAL can play a very important role in the diagnosis of respiratory tract
infections. All these analyses are usually readily performed in a moderately equipped cytological laboratory.
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Introduction
By simple definition bronchoalveolar lavage (BAL)
denotes putting saline in the lung via flexible broncho-
scope, then removing as much as possible to examine
cells and non-cellular components.
BAL was introduced into clinical practice almost 40
years ago. Since, it has gained universal acceptance as a
minimally invasive procedures that enables sampling of
respiratory tract contents of the distal parts of the lungs,
the parenchyma. Analysis of bronchoalveolar lavage fluid
(BALF) aids in the diagnosis and management of various
diffuse lung disease. In this article we will focus on sig-
nificance of the evaluation of the cellular component of
the lung lavage fluid in the recognition and diagnose of
DLD, the task completed in the cytological laboratory.
The search for the incriminating microbes is also very
important and is performed on the regular basis. It is to
note that numerous other analysis, especially of the
acellular components of the BAL fluid, are also possible,
but they are usually not done except in the research pro-
jects. Examination of BAL cells or acellular components
of BAL via gene microarray technology or proteomic
analysis may allow BAL to assume a more prominent
role in diagnosis and management of lung disease in the
near future.
Bronchoscopy with BAL fluid analyses is indicated if
the patient is fit for the procedure and the clinical and
high-resolution computed tomography (HRCT) findings
suggest a condition in which BAL is likely to be diagnos-
tic or significantly increases diagnostic confidence. Even,
if the BAL is not diagnostic, it can provide findings that
are inconsistent with suspected diagnoses and help focus
attention on prosecution of alternative diagnoses.
Procedures
Bronchoscopy and bronchoalveolar lavage
By the aid of bronchoscope it is not possible to inspect
the parenchyma, but the precise and detailed inspection
of the bronchial mucosa, and additional techniques, like
bronchoalveolar lavage (BAL) and transbronchial lung
biopsy, enable us to gain enough information about the
pulmonary parenchyma.
The lung lavage fluid is obtained during fiberbroncho-
scopy, usually along with other procedures like trans-
bronchial lung biopsy, transtracheal and transbronchial
fine needle aspiration biopsy of lymph nodes, catheter as-
piration, and others.
Lung lavage is a procedure which enables to obtain
cells and non-cellular components from the peripheral,
bronchoalveolar compartment of the lung.
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Recommendations for performing and analyzing BAL
have been published by both the European Respiratory
Society and the American Thoracic Society1,2. Since, some
recommendations have been reconsidered. For instance,
traditionally the middle lobe and lingula are lavaged in
patients with DLD because they are easily accessible and
the probability to gain satisfactory return of the fluid is
greatest. The almost ubiquitous usage of HRCT images
to target areas of active pathological process, especially
the ground glass pattern areas, changed this approach
because lavaging these areas increases the likelihood of
obtaining diagnostic, retrieved BAL fluid3,4. Also, it is
well known that the amount of the returned lavage fluid
is of great interest. But, if the patient is lavaged in order
to confirm malignant cells, Pneumocystis jiroveci or other
infection, the amount is not that important. In the case
of DLD, a good representation of the alveolar space
should be obtained. It has been shown that patients with
greater than 5% retrieved fluid have a higher diagnostic
yields5, but ideally the percentage for patients with sus-
pected DLD would be at least 39%.
BAL fluid should be processed and analyzed to exam-
ine cellular components and to detect infectious agents.
Examination of cellular components.
The examination of the inflammatory cell population
of lung lavage fluid is the most important and most bene-
ficial of all the analyses of lung lavage fluids, especially in
differentiation between diverse diffuse lung diseases.
One has to take into consideration that there are several
limitations, several factors that may affect the cellular
population of the lavage sample. Different laboratories
use different steps in this process, which concerns the
preparation of the cells for different cell count, cellular
staining, the number of cells on which the counting has
been performed, and last, but not the least important are
the skills of the reader of the slides. The standard proce-
dure of examination of cellular populations of lung la-
vage fluid, routinely performed at the Cytological Labo-
ratory at the University Hospital for Lung Disease »Jor-
danovac«, Zagreb, will be described.
It is very important to process the lung lavage fluid
immediately in order to preserve the cell viability, be-
cause in the contrary it becomes unsuitable for analysis.
But prior to the laboratory processing it is mandatory
to asses the macroscopic feature of the lavage fluid. In
non-smokers the fluid is slightly turbid and in the smok-
ers more turbid and grayish. If the patient has been ex-
posed to coal particles or gunpowder the lavage fluid is
dark in appearance, and the sedimentation of particles to
the bottom of the container is observed. In the cases of
acute alveolar hemorrhage each consecutive retrieved
fraction of lavage fluid becomes more hemorrhagic. This
is in contrast with the bleeding from the central airways
when the first fraction is the most bloody. In case of
chronic alveolar hemorrhage, when the alveoli are filled
with siderophages, the lavage color will be orange-brow-
nish. This is very important finding and demands fur-
ther processing with Pearl’s blue iron staining. Thick,
white lavage fluid which sometimes aggravates the aspi-
ration through the bronchoscope may indicate the possi-
bility of pulmonary alveolar proteinosis; in the case of al-
veolar proteinosis, with periodic acid-Schiff reagents the
lavage fluid turns red.
At the beginning of the processing of the lavage fluid
small amount of the fluid is separated for bacterial cul-
ture. Routine microbiological analysis includes nonspe-
cific bacterial culture, direct fluorescent microscopy for
acid resistant bacilli, and mycobacterial culture. If neces-
sary the processing is broadened and the material can be
cultivated for anaerobic bacteria and fungi, gene probes
for mycobacteria and atypical bacteria (Chlamydia pneu-
moniae, Legionella, etc.) can be added, as well as staining
with Kwik-Diff to detect Pneumocystis jiroveci.
The total cell count in lung lavage fluid is determined
by hemocytometer6 or by counting the cells in the Bür-
ker-Tierck canister.
Following the filtration and removal of the mucus, the
fluid is centrifuged for 5 minutes, in the cytocentrifuge,
at the speed of 1000 rpm. Thus the cellular component is
separated from the lavage supernatant. Supernatant is
suitable for biochemical and immunological analysis, and
various extracellular components like albumin, enzymes,
enzyme inhibitors (neutrophil elastase, myeloperoxida-
se), prostaglandins, cytokines, chemokines, reactive oxy-
gen species, and components of surfactant can be detec-
ted, and their significance in various pathological condi-
tions studied7. The results of the estimation of BAL
acellular components of BAL via proteomic analysis are
promising8.
Cell pellet is suitable for cytological and immuno-
cytochemical analyses, flow-cytometry and cultures of
various microbes. Cytospin preparations are routinely
stained according to May-Grenwalld-Giemsa method, and
along the quality cell analysis, the quantity tests are per-
formed as well. Examination of at least 600 nucleated
white blood cells randomly, on a single slide is performed.
The number of obtained cells is expressed as percentage.
The presence of more than 5% squamous epithelial cells
in BAL indicates cell contamination, and thus makes the
sample inadequate for diagnosis of DLD. If the sample is
adequate, the counting on 400–600 cells is repeated, but
this time squamous epithelial cells are omitted. The
numbers obtained represent lung lavage cell profile, ex-
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TABLE 1
NORMAL VALUES OF CELLS IN BRONCHOALVEOLAR LAVAGE
FLUID
Non-smokers Smokers
Alveolar macrophages 85–95% 90–95%
Lymphocytes 7.5–12.5% 3.5–7.5%
Neutrophils <2% <2.5%
Eosinophils <1% <1%
Mast cells <1% <1%
CD4/CD4 ratio
0.5–6.4
(median 2.6)
0.3–28.1
(median 6.5)
pressed as an absolute number out of 200 cells, or as a
percent. Lung lavage cell profiles differ slightly between
smokers and non-smokers, mostly in that the smokers
generally have significantly increased total BAL cell count,
as well as total macrophages and neutrophils per mL of
BAL fluid. Table 1 shows normal values of the lung la-
vage cell profiles in smokers and non-smokers that are
used at the University Hospital for lung Disease, Zagreb.
Increased percentage of particular cell line, indicates the
alveolitis and depending upon the cell line that is in-
creased we recognize lymphocytic, neutrophil, eosinophil
and mixed alveolitis. Elderly subjects appear to have in-
creased percentages of lymphocytes and neutrophils in
the differential cell counts, suggesting that advanced age
may affect BAL cell differentials9. Additionally, the total
volume of retrieved fluid declines with advanced age due
to loss of elastic recoil and airway tethering that makes
airways more likely to collapse with negative pressure.
Except the quantity analysis of inflammatory popula-
tions of lung lavage cells, it is of utmost importance to
perform the quality analysis, to look for malignant cells,
microorganisms and inorganic particles (Table 2). It is
possible to do some additional testing, according to previ-
ous BAL findings or indications posed by the cytologist or
clinician. To detect Pneumocystis jiroveci it is necessary
to stain fresh smears with quick stain according to Pa-
panicolaou and Kwik-Diff. Subsequently it is possible to
stain the smears for pulmonary alveolar proteinosis (PAS
– periodic acid-Schiff) and siderophages (Pearl’s blue
iron staining)10. The severity of the bleeding can be
quantified using the Golde score which represents a nu-
merical scale based on the blue intensity of macrophages
on an iron stain from 0 to 4; the maximum score is 400
and scores less than 20 are considered normal11. The
Golde score is not routinely used, instead the percentage
of sideropages is counted. The percentage of sideropha-
ges equal or greater than 20% is sufficient to affirm the
presence of diffuse alveolar hemorrhage12. An increase of
BAL CD1a positive cells (Langerhans cells-LC) by immu-
nocytochemical analyses, of more than 5% is detected al-
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TABLE 2
LUNG LAVAGE CELLS PROFILES IN DIFFUSE LUNG DISEASE
Disease
Alveolar
macrophages
Ly N. gra Eo gra Other cells, spetial stains CD4/CD8 ratio
Sarcoidosis ++ =/+ =/+ /=
Idiopathic pulmonary fibrosis + ++ + =
BOOP Foamy + + + 
Nonspecific interstitial pneumonia + + + 
Acute interstitial pneumonia = ++ =
Atypical pneumocytes type II,
amorphous material –frag-
ments of hyaline membranes
=
RB-ILD/DIP Cigarette
pigment
= ++ = =
Connective tissue disease + + =/+ /=/
Pneumoconioses
Coal pigment
or asbestos
bodies, silica…
+ + –
Beryllium-sensitized
BAL lymohocytes 
Hypersensitive pneumonitis Foamy ++ + =/+
Sporadically plasma cells
and mastocytes /=
Drug-induced pneumonitis Foamy ++ + +
Sporadically plasma cells
and mastocytes /=
Eosinophilic pneumonia + = ++ 25% Sporadically plasma cells 
Diffuse alveolar hemorrhage
Siderophages
20%
=/+ + =/+
Pearl’s blue iron staining
(Golde score)
=
Alveolar proteinosis Foamy + = = PAS – periodic acid-Schiff 
Langerhans’scell histiocytosis = = =/+
Langerhan’s cells – CD1a
and protein 100 positive
=
Carcinomatous lymphangiosis.
Bronchioalveolar carcinoma
Malignant cells
Pneumocystis jiroveci Kwik-Diff
Tuberculosis Ziehl-Neelsen
Fungal infection
Gomori methenamine
silver (GMS)
BOOP – bronchiolitis obliterans organizing pneumonia, RB – ILD/DIP – respiratory bronchiolitis associated interstitial lung disease
most exclusively in pulmonary LCH; the specificity of the
test is high, but the sensitivity is low13.
Cell subpopulations are readily detected by the aid of
flow cytometer or immunocytochemichal method. The
flow cytometry is a swift and simple method, but it can be
performed only on the fresh samples, and connotes addi-
tional apparatuses and laboratory equipment. Immuno-
cytochemical analysis is long-lasting and complicated,
but it is very sensitive and perfectly depicts the cell mor-
phology. It is performed on the non-stained smears which
can be old as much as 7 days. And, above all, it is only
necessary to have the light microscope and a panel of
monoclonal antibodies which are used routinely (CD1a,
CD2, CD19, CD4 and CD8). Taking into consideration all
the advantages and all the limitations, it would be ideal
to combine both methods. In our Institution we use the
flow cytometry as the routine method, and immuno-
citochemical analysis only if indicated.
Diagnostic Value
Diffuse lung disease
Diffuse lung diseases14,15 are a heterogeneous group
with the common characteristic of diffuse infiltration of
lung parenchyma with inflammatory or malignant cells,
connective tissue or liquids, which disturb the passage of
oxygen into the blood. The course of the disease may be
acute but more often it is chronic. These diseases make
about 15% of the pulmonary pathology. Most often they
are classified into the group of known and a group of un-
known causes. The significance of precise and thorough
history of the diseases is of utmost importance, may be
more important than in any other field of pulmonary pa-
thology, because along with the systematic physical ex-
amination, it represents a key to the installation of work-
ing, sometimes final diagnosis and rational planning of
the diagnostic procedures.
All DLDs, however, have certain common clinical, ra-
diologic, and physiologic features that should be recogni-
zed.
The utilization of BAL for diagnostic purposes has
significantly improved the diagnostic work-up of diffuse
lung disease. BALF inflammatory cell populations in
DLD usually differ from the findings in healthy parsons.
There are only some conditions where BALF analysis re-
sults are diagnostic and provide conclusive evidence of
the cause of diffuse pathological lung conditions16,17.
In general, evaluation of BALF data is more often di-
agnostic in patients with acute symptoms. In a number
of diseases and/conditions such as diffuse alveolar hem-
orrhage, sarcoidosis, hypersensitivity pneumonitis, drug-
-induced pneumonitis, eosinophilic lung disease, Langer-
hans cell hystiocytosis (LCH) (Figure 1), alveolar protei-
nosis (Figure 2), occupationally-induced lung diseases
(Figure 3), and infections and malignancies (Figure 4)
which can mimic diffuse lung disease, lavage can be diag-
nostic (Table 3). But there are many diseases and condi-
T. Pero{-Golubi~i} and S. Smojver-Je`ek: Lung Lavage Cell Profiles in Diffuse Lung Disease, Coll. Antropol. 34 (2010) 1: 327–335
330
Fig. 1. CD1a positive cell (arrow) in Langerhans cell hystiocy-
tosis (LCH), immunocytochemistry in BALF, cytospin, original
magnification 400x.
Fig. 2. PAS positive globules, background and macrophages in
alveolar proteinosis, BALF, cytospin, original magnification 400x.
Fig. 3. Ferruginous body in unstained slide, BALF, cytospin, ori-
ginal magnification 400x.
tions where it is an accessory method, still helpful be-
cause it either narrow the diagnosis or focuses attention
on prosecution of alternative diagnoses.
The significant increase of one particular inflamma-
tory cell line in BALF narrows the differential diagnosis
(Table 4). In combination with high resolution computed
tomography (HRCT) and clinical features, it can be hi-
ghly suggestive or even diagnostic of certain DLD. Also,
the presence of certain cells that are normally not found
in BALF is sometimes helpful. These cells are: plasma
cells, pigmented macrophages, foamy macrophages, and
reactive type II pneumocytes (typical and atypical).
Lymphocytes
The increased BAL lymphocyte count is often present
in a number of DLD like sarcoidosis, hypersensitivity
pneumonitis, connective tissue disease, drug induced pneu-
monitis, interstitial pneumonias i.e. cellular non-specific
interstitial pneumonitis (NSIP-cellular) and bronchio-
litis obliterans organizing pneumonia (BOOP), inflam-
matory bowel disease, occupational lung disease (i.e.
chronic beryllium disease, asbestosis), infection (myco-
bacteria, viral) and radiation pneumonitis. BALF lym-
phocytosis above 25% is quite probably caused by chronic
granulomatous inflammation, sarcoidosis18, hypersensi-
tivity pneumonitis, cellular NSIP, chronic beryllium dis-
ease, viral infection or by drug toxicity. Extreme lympho-
cytosis, above 50% with supportive history of exposure, is
highly suggestive of hypersensitivity pneumonitis19.
According to the 2002 ATS/ERS Consensus Classifica-
tion, a confident diagnosis of idiopathic pulmonary fibro-
sis (IPF) without surgical lung biopsy is made with con-
sistent clinical/physiological findings and the typical fea-
tures on high-resolution computed tomography (HRCT).
Bronchoalveolar lavage (BAL) and/or transbronchial bi-
opsy, one of four major criteria in the 2000 ATS/ERS IPF
Statement, was no more essential in the diagnostic algo-
rithm of 2002 ATS/ERS Consensus Classification. Re-
cently, the group of researcher20 reevaluated the addi-
tional utility of BAL for the diagnosis of IPF. The 74
patients met all the criteria recommended in the 2002
ATS/ERS Consensus Classification for making a diagno-
sis in the absence of surgical biopsy. The final diagnosis
was made with further examinations, including patho-
logical analysis, in patients who showed inconsistent
findings for IPF on BAL. A cut-off level of 30% for lym-
phocytes in BAL demonstrated a favorable discrimina-
tive power for the diagnosis of IPF. Six of the 74 patients
(8%) showed a lymphocytosis of 30% or greater in BAL.
Their final diagnoses were idiopathic nonspecific inter-
stitial pneumonia (n=3) and extrinsic allergic alveolitis
(n=3). The change in perception of the diagnosis was val-
idated by a surgical biopsy in two cases and by subse-
quent outcome in four cases. The conclusions were that
the BAL lymphocytosis changed the diagnostic percep-
tion in six of 74 patients who would have been misdia-
gnosed as having IPF without BAL. This was a proof that
certain diagnosis is readily suspected upon high lym-
phocytosis, and also that BAL should be performed in
clinical settings suspicious of IPF.
CD4+:CD8+ T lymphocyte ratio in diseases with
lymphocytic alveolitis shows different values (Table 5)21.
High values increase the likelihood of sarcoidosis; the ra-
tio higher than 3.5 is rather specific for sarcoidosis22,23
but the sensitivity is quite low.
Neutrophils
Extreme values of BALF neutrophils, above 50% stron-
gly support a diagnosis of suppurative lung process or
diffuse lung damage. Neutrophil alveolitis, with values
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TABLE 3
BROCHOALVEOLAR LAVAGE FLUID ANALYSIS HELPFUL IN ESTABLISHING THE DIAGNOSIS OF PARTICULAR DLD
Disorder/disease
Diffuse lung diseases
Diffuse alveolar hemorrhage (DAH); Sarcoidosis; Hypersensitivity pneumonitis (HP); Drug induced
lung disease; Eosinophilic lung disease; Langerhans cell histiocytosis (LCH); Pulmonary alveolar
proteinosis (PAP)
Acute onset DLD Adult respiratory distress syndrome (ARDS); Acute interstitial pneumonia (AIP)
Occupational lung disease Chronic beryllium disease; Asbestosis; Silicosis
Pulmonary malignancies Lymphangiitis carcinomatosis; Bronchoalveolar carcinoma (BAC); Lymphoma and other malignancies
Pulmonary infection
Immunocompromised host with infiltrates; Ventilator-associated pneumonia; Evaluation of persistent
infiltrates/inadequate clinical response
Fig. 4. Cluster of adenocarcinoma cells in BALF, cytospin, MGG
staining, original magnification 400x.
that are usually not increased at high rates, is also de-
tected in number of other processes. For instance, the
number of neutrophils in bronchoalveolar lavage fluid
distinguishes between sarcoidosis patients who demon-
strate remission and those having a more severe course
of the disease; increased BALF neutrophils announce the
severe course24.
Eosinophils
Increase lavage eosinophils, especially extreme values
are very helpful in narrowing the differential diagnosis of
DLD. BALF eosinophils equal or above 25% are highly
likely caused by eosinophilic lung disease, especially eosi-
nophilic pneumonia, but also Churg-Strauss or hypereo-
sinophilic syndrome25,26.
Mast cells
Mast cells play an important role in tissue inflamma-
tion, fibrosis and remodeling. They are found in broncho-
alveolar lavage fluid (BAL) of healthy persons only in
small numbers. Increased number is associated with hy-
persensitivity pneumonitis, drug-induced lung disease,
BOOP27, connective tissue diseases, eosinophilic pneu-
monia, IPF, malignancies and sarcoidosis.
Plasma cells
Plasma cells are normally absent in bronchoalveolar
lavage (BAL) fluid, but if detected they facilitate differ-
entiation among diffuse pulmonary disorders. They are
observed in hypersensitivity pneumonitis, drug-induced
pneumonitis, eosinophilic pneumonia, malignancies and
infection (Legionella, Pneumocystis jiroveci)28.
Pigmented macrophages
The pigmented macrophages are alveolar macropha-
ges whose cytoplasm contains divers materials which
they have phagocytosed, such as carbon, cigarette pig-
ment, hemosiderin, cell fragments, foreign bodies (asbes-
tos bodies, pseudo-asbestos bodies) or debris. Their pres-
ence is helpful to diagnose various pneumoconioses, dif-
fuse alveolar hemorrhage, and respiratory-bronchiolits
interstitial lung disease (RB-ILD).
Foamy macrophages
Foamy macrophages are alveolar macrophages whose
cytoplasm demonstrates complete vacuolisation. The pre
sence of these foamy alveolar macrophages is usually
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TABLE 4
INCREASED BALF INFLAMMATORY CELL POPULATIONS IN DLD
Balf cells Diffuse lung disease
Lymphocytes 15%
(Lymphocytic alveolitis)
Sarcoidosis; Hypersensitivity pneumonitis; Connective tissue disease; Drug induced pneumonitis; In-
terstitial pneumonias: NSIP*-cellular, BOOP**; Inflammatory bowel disease; Occupational lung dis.
(e.g. chronic beryllium dis.); Infection (mycobacteria, viral); Radiation pneumonitis
Neutrophils 5%
(Neutrophilic alveolitis)
Infection; Lung injury; Interstitial pneumonias: BOOP, DIP'' IPF'''', NSIP); Connective tissue diseases;
Drug-induced pneumonitis; Hypersensitivity pneumonitis; Occupational lung disease; Aspiration pneu-
monia; Sarcoidosis
Eosinophils 3%
(Eosinophilic alveolitis)
Eosinophilic pneumonia; Drug-induced pneumonitis; Churg-Strauss syndrome; Hypereosinophilic syn-
drome; Parasitic infection; Interstitial pneumonias. IPF, NSIP-fibrotic; Connective tissue diseases;
Pneumocystis jiroveci pneumonia
Mast cells Hypersensitivity pneumonitis; Drug-induced pneumonitis; IPF: Connective tissue diseases; BOOP;
Eosinophilic pneumonia; Malignancy; Sarcoidosis
Plasma cells Hypersensitivity pneumonitis; Drug-induced pneumonitis; Eosinophilic pneumonia; Malignancy; Infec-
tion (Legionella, Pneumocystis)
Pigmented macrophages Pneumoconioses; Diffuse alveolar hemorrhage; RB-ILD
Foamy macrophages Aspiration pneumonia; Drug-induced lung disease; Hypersensitivity pneumonitis; Pulmonary alveolar
proteinosis; BOOP
Reactive type II
pneumocytes
Systemic inflammatory response syndrome; Alveolar hemorrhage; Ventilator-associated pneumonia;
Pneumocystis jiroveci pneumonia; Hypersensitivity pneumonitis; Drug-induced lung disease
*NSIP – non-specific interstitial pneumonia, **BOOP – bronchiolitis oblterans organizing pneumonia, '' DIP-desquamative interstitial
pneumonia, ''''IPF – idiopathic pulmonary fibrosis, °RB-ILD – respiratory bronchiolitis interstitial lung disease
TABLE 5
CD4/CD8 RATIO IN DISEASES WITH LYMPHOCYTIC ALVEOLITIS
CD4:CD8 increased CD4:CD8 normal CD4:CD8 decreased
Sarcoidosis Tuberculosis
Hypersensitivity
pneumonitis
Beryllium disease
Lymphangitic
carcinomatosis
BOOP*
Asbestos-induced
alveolitis
Silicosis
Alveolar proteinosis HIV infection
Crohn’s disease
Drug-induced
pneumonitis
Connective-tissue
disorders
*BOOP – bronchiolitis obliterans organizing pneumonia
non-specific, but they are frequently detected in BALF of
patients with aspiration pneumonia, drug-induced lung
disease, hypersensitivity pneumonitis, pulmonary alveo-
lar proteinosis and BOOP.
Reactive type II pneumocytes
The reactive type II pneumocytes in bronchoalveolar
lavage (BAL) fluid samples are observed as large cells
with a high nuclear to cytoplasmic ratio and deeply
blue-stained, vacuolated cytoplasm (Figure 5). The high-
est prevalence of reactive type II pneumocytes is detected
in patients with systemic inflammatory response syn-
drome – SIRS (SIRS is nonspecific and can be caused by
ischemia, inflammation, trauma, infection, or a combina-
tion of several insults)29 and alveolar hemorrhage. In ad-
dition, they occur in ventilator-associated pneumonia,
Pneumocystis jiroveci pneumonia, hypersensitivity pneu-
monitis and drug-induced pulmonary disorders30.
The group of authors31 aimed to quantify how the
likelihood for a given diagnosis changes with the knowl-
edge of bronchoalveolar lavage cell differentials. As an
initial estimate (a priori probability), frequencies of final
diagnoses were taken. Using categorizations for cell dif-
ferentials, a posteriori probabilities were then derived
for each disease. The analysis was performed in three of
five groups of diagnoses suspected prior to BAL: intersti-
tial lung disease, inflammatory disease, or lung tumor
mimicking DLD. Overall, out of 1 971 patients, 18.3%
had sarcoidosis, 7.7% usual interstitial pneumonia (UIP),
4.4% hypersensitivity pneumonitis (HP) and 19.0% tu-
mors. In the group with suspected DLD, the likelihood
for sarcoidosis increased from 33.7 to 68.1% when lym-
phocyte numbers were 30–50% and granulocyte numbers
were low; the likelihood for UIP increased from 15.8 to
33.3% when lymphocyte numbers were 30% with granu-
locytes elevated. CD4/CD8 was informative, especially in
sarcoidosis and HP. Despite considerable increases, the
likelihood of rare diseases rarely reached appreciable val-
ues. Similar results were obtained in the other two
groups of suspected diagnoses. In conclusion, these data
suggest that bronchoalveolar lavage cell counts per se
provide substantial diagnostic information only in rela-
tively frequent diseases, such as sarcoidosis and usual in-
terstitial pneumonia, and are less helpful in infrequent
diseases.
Acute onset DLD
Acute onset DLD are the group of diseases character-
ized by duration of less than 4 weeks, dyspnoa, hypo-
xemia, and diffuse lung infiltrates upon radiological ex-
amination, not caused by know agent, including ARDS.
Apart of the infection, acute onset DLDs include acute
interstitial pneumonia (AIP), acute eosinophilic pneumo-
nia (EP), acute BOOP, drug toxicity or acute exacerba-
tion of unrecognized idiopathic pulmonary fibrosis (IPF).
Bronchoalveolar lavage is helpful in diagnosing alveolar
hemorrhage and infection, increased eosinophils point to
eosinophilic pneumonia (EP) and lymphocytes indicate
HP or drug toxicity, especially if mast cells or plasma
cells are present.
Occupational lung disease
Occupational lung diseases presenting with DLD fea-
tures include asbestosis, coal worker’s pneumoconiosis,
silicosis, beryllium disease, hard metal pneumoconiosis,
aluminum associated lung disease, flavorings workers
bronchiolitis obliterans (popcorn workers’ lung) and hy-
persensitivity pneumonitis of various causes.
The influence of nanoparticles on lung health has re-
cently been raised. Nanoparticles, classified as anthro-
pogenic and natural particles, and fibers of diameters
less than 100 nm, have unrestricted access to most areas
of the lung due to their size. Size relates to the deposition
efficiency of the particle, with particles in the nano-range
having the highest efficiencies. The deposition of nano-
particles in the lung can lead to chronic inflammation,
epithelial injury, and further to pulmonary fibrosis. Al-
though studies of nanoparticle toxicity have focused on
lung disease the molecular link between nanoparticle ex-
posure and lung injury remained unclear. It has recently
been show that cationic Starburst polyamidoamine den-
drimer (PAMAM), a class of nanomaterials that are being
widely developed for clinical applications can induce acu-
te lung injury in vivo. PAMAM triggers autophagic cell
death by deregulating the Akt-TSC2-mTOR signaling
pathway32.
The contribution of BALF analysis in the evaluation
of various occupational lung diseases until now has not
been marked, except for diagnosing the hypersensitivity
pneumonitis. It has already been mentioned that high
lymphocyte counts, above 50% and low CD4/CD8 ratio
are helpful in these respect. Also, the detection of silica
particles and asbestos bodies in BALF33 is usually per-
formed if pneumoconiosis is suspected, but it is not pos-
sible to distinguish between sheer exposure and dust-in-
duced disease.
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Fig. 5. Reactive pneumocyte (arrow) in BALF, cytospin, MGG stai-
ning, original magnification 400x.
Malignancies mimicking DLD
Bronchoalveolar lavage is a useful diagnostic tool in
diffuse lung malignancies which mimic DLD, and do not
involve the bronchial structures visible by bronchoscope.
Adenocarcinoma and tumors with lymphangitic growth
patterns are easily diagnosed by bronchoalveolar lavage;
in these cases the diagnostic yield reported is higher than
80%. In hematologic malignancies the diagnostic yield is
quite good in secondary diffuse indolent B-cell lympho-
mas and in primary B-cell lymphomas of mucosa-associ-
ated lymphoid tissue (MALTQ3) type but low in Hodgkin
disease34. Application of immunophenotypic and gene re-
arrangement analysis35 and clonality investigations is
useful to identify pulmonary lymphomas36.
Disorders in which bronchioloalveolar cell hyperpla-
sia/dysplasia is a significant morphological component
may have cytological features in bronchoalveolar lavage
fluid that mimic lung neoplasms like acute respiratory
distress syndrome (ARDS), acute interstitial pneumoni-
tis (AIP), and acute exacerbation of idiopathic pulmo-
nary fibrosis.
Conclusion
Lung lavage cell profile analyses are helpful in diag-
nosing of various diffuse lung disease, but it applies only
to a small number of diseases and/conditions such as dif-
fuse alveolar hemorrhage, sarcoidosis, hypersensitivity
pneumonitis, drug-induced pneumonitis, eosinophilic lung
disease, Langerhans cell hystiocytosis (LCH), alveolar
proteinosis, and to some extent to occupationally-indu-
ced lung diseases. Also lavage can be helpful to diagnose
infections and malignancies which can mimic diffuse
lung disease.
There are numerous, other DLDs where it is an acces-
sory method, but nevertheless helpful because it either
narrow the diagnosis or focuses attention on prosecution
of alternative diagnoses. Except the quantity analysis of
inflammatory populations of lung lavage cells, it is of ut-
most importance to perform the quality analysis, to look for
malignant cells, microorganisms and inorganic particles.
New techniques, for instance gene microarray tech-
nology or proteomic analysis may allow BAL to assume a
more prominent role in diagnosis and management of
lung disease in the near future.
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STANI^NI SASTAV BRONHOALVEOLARNOG LAVATA U DIFUZNIM BOLESTIMA PLU]A
S A @ E T A K
Standardni armamentarium testova kojima se koriste pulmolozi su laboratorijski testovi, testovi plu}ne funkcije,
razli~te slikovne tehnike (konvencionalni rendgenolo{ki pregled, kompjutorizirana tomografija i druge) i patohisto-
lo{ka analiza bioptata. Minimalno invazivna tehnika bronhoalveolarne lava`e, uz ranije spomenute tehnike, va`an je
dijagnosti~ki instrument koji olak{ava dijagnostiku razli~itih difuznih plu}nih bolesti. Analiziraju se upalne stanice
bronhoalveolarnog lavata, tra`e se maligne, i u odre|enim okolnostima vr{e se dodatna bojenja kako bi se detektirale i
neke druge stanice. Dodatno, analiza lavata je vrlo zna~ajna u dijagnostici infekcija respiratornog trakta. Sve ove ana-
lize mogu se izvesti u umjereno ekipiranom citolo{kom laboratoriju.
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